Literature DB >> 8866423

Enhanced superoxide dismutase-2 immunoreactivity of astrocytes and occasional neurons in amyotrophic lateral sclerosis.

H G Blaauwgeers1, J M Vianney de Jong, H W Verspaget, F M van den Berg, D Troost.   

Abstract

The recent discovery of missense mutations in the superoxide dismutase (SOD)-1 gene as a cause of familial amyotrophic lateral sclerosis (ALS) and the ensuing description of transgenic SOD-1 mutant mouse models have focussed scientific interest on free radical scavenging mechanisms in all other familial (FALS) and sporadic (SALS) forms of the disease. We have compared the presence of intracellular cytosolic copper-zinc SOD-1 and mitochondrial manganese SOD-2 in the CNS from FALS and SALS patients and from non-neurological controls by immunohistochemical assessment, in the knowledge that no SOD-1 mutations have been found in any of 18 Dutch ALS pedigrees. ALS specimens from the motor cortex and the spinal cord presented enhanced SOD-2 immunoreactivity, especially of astrocytes and occasionally of neurons. Astrocyte staining appeared to be increased at the cerebral cortical and the spinal cervical and lumbar levels, but was only slightly increased in the thoracic anterior horns and not at all in the brain stem. This indicates that, by the time of death, the disease had burnt out in the brain stem and thoracic cord. Increased staining of neurons was limited to the small lateral and dorsal nuclei of the spinal cord. FALS and SALS cases exhibited the same staining patterns. SOD-1 immunoreactivity did not differ between disease and control specimens. SOD-1 and -2 staining was normal in the ALS cortical, brain stem and spinal motoneurons. This suggests that SALS and non-SOD-1 mutant FALS are not accompanied by loss of SOD-1 or -2 protein. An enzyme-linked immunosorbent assay revealed no differences in SOD-1 and SOD-2 levels between ALS patients and controls. Our major finding of locally increased SOD-2 immunoreactivity of astrocytes in FALS and SALS specimens, probably reflects reactive fibrillary and protoplasmatic gliosis in areas of ongoing degeneration but may also result from an attempt at compensation for free radical injury.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866423     DOI: 10.1016/0022-510x(96)00110-4

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

Review 1.  Mitochondrial involvement in amyotrophic lateral sclerosis: trigger or target?

Authors:  Sandra R Bacman; Walter G Bradley; Carlos T Moraes
Journal:  Mol Neurobiol       Date:  2006-04       Impact factor: 5.590

Review 2.  Nitric oxide-mediated oxidative damage and the progressive demise of motor neurons in ALS.

Authors:  Derek A Drechsel; Alvaro G Estévez; Luis Barbeito; Joseph S Beckman
Journal:  Neurotox Res       Date:  2012-04-10       Impact factor: 3.911

3.  Role of astrocytes in pathogenesis of ischemic brain injury.

Authors:  B Gabryel; H I Trzeciak
Journal:  Neurotox Res       Date:  2001-04       Impact factor: 3.911

4.  Cultivating stem cells for treating amyotrophic lateral sclerosis.

Authors:  Shengwen Calvin Li; Hong Zhen Yin; William G Loudon; John H Weiss
Journal:  World J Stem Cells       Date:  2012-12-26       Impact factor: 5.326

Review 5.  Gliotransmitter Release from Astrocytes: Functional, Developmental, and Pathological Implications in the Brain.

Authors:  Kazuki Harada; Taichi Kamiya; Takashi Tsuboi
Journal:  Front Neurosci       Date:  2016-01-12       Impact factor: 4.677

6.  Meta-analysis of mouse transcriptomic studies supports a context-dependent astrocyte reaction in acute CNS injury versus neurodegeneration.

Authors:  Sudeshna Das; Zhaozhi Li; Ayush Noori; Bradley T Hyman; Alberto Serrano-Pozo
Journal:  J Neuroinflammation       Date:  2020-07-31       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.